BridgeBio Pharma

Oct 22, 2019

BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference

Nov 12, 2018

BridgeBio Pharma LLC Signs Joint Collaboration Agreement with Cincinnati Children's to Accelerate Development of Genetic Disease Therapeutics

Jun 18, 2018

NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics

Jun 11, 2018

BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Origin Biosciences to Develop and Commercialize Therapy

Jan 30, 2018

BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

Nov 15, 2017

Preclinical Data Demonstrates Potential of Eidos Therapeutics' Lead Compound for the Treatment for Transythyretin Amyloidosis

Nov 09, 2017

Eidos Therapeutics to Present Data on its Potential Treatment for Transthyretin Amyloidosis at the American Heart Association

Sep 28, 2017

Eidos Therapeutics Initiates First Clinical Study for AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis as Chief Business Officer

Sep 13, 2017

BridgeBio Pharma expands investor base, raising an additional $135 million, and discloses genetic disease pipeline programs